^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
EndoPredict®

Type:
Laboratory Developed Test
Evidence

News

6d
Early Diagnostic Prediction of Infective Endocarditis: Development and Validation of EndoPredict-Dx. (PubMed, Diagnostics (Basel))
The EndoPredict-Dx score accurately predicted the likelihood of infective endocarditis using clinical and laboratory data collected at admission.
Journal
|
CRP (C-reactive protein)
|
EndoPredict®
1m
Subtype by PAM50 changes after Neoadjuvant Endocrine therapy, from A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy plus Palbociclib versus Hormonal Therapy plus Placebo in ER+HER2- Operable Breast Cancer (SABCS 2024)
Hormonal therapy consisted of letrozole for post-menopausal patients and tamoxifen plus LH-RH agonist for pre/peri-menopausal patients. Neoadjuvant endocrine therapy for 16 weeks changes subtype classification by PAM50 from luminal B to luminal A and the ROR drastically. Greater effects were noted for the combination, not statistically significant, but this warrants further investigation in a larger cohort. There were 3 HER2-enriched cases with poor response, but this was not significant because of the small sample size.
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
Ibrance (palbociclib) • tamoxifen • letrozole
1m
Current Endocrine/Systemic Treatment Landscape of ER+ HER2 negative early-stage Breast Cancer: First Data from the RESCUE trial (SABCS 2024)
Objective: By analyzing baseline and follow up data from RESCUE, we describe the current (neo)adjuvant treatment landscape for pt with ER+ HER2neg early-stage breast cancer including: type of endocrine agents used, addition of GnRH analogs (GnRHAa)/ovarian function suppression (OFS) to ET in premenopausal pt, use of chemotherapy and use of bone modifying agents (Bisphoshonates or Denosumab) in the adjuvant setting...In these 57 pt, GnRHa/OFS was recommended to be combined with an aromatase inhibitor as initial ET in 15 cases (3,8% of premenopausal pt) and with tamoxifen in 41 cases (10,4% of premenopausal pt)... These real world data show that in spite of existing guideline recommendations for the use of GnRHa/OFS in premenopausal women with early luminal breast cancer at higher risk for relapse, this is not routinely implemented. Therefore, regarding the ET recommendation, this patient cohort might be undertreated. Follow up data on actually received ET (including +/- GnRH) and CTX (including +/- anthracyclines) will be presented in detail.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
EndoPredict®
|
tamoxifen • Prolia (denosumab)
1m
Comparison of different gene expression tests in breast cancer: poor correlation of Prosigna, EndoPredict and MammaPrint (SABCS 2024)
Consequently, those tests cannot be employed interchangeably. The results emphasize the pressing necessity for further comparative analysis of multi-genomic tests to prevent misclassification of risk class and disease recurrence risk in breast cancer patients.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • EndoPredict®
1m
New P2 trial
|
CDK4 (Cyclin-dependent kinase 4)
|
EndoPredict®
|
letrozole • AiRuiKang (dalpiciclib)
2ms
Clinical
|
HR positive
|
EndoPredict®
2ms
Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer. (PubMed, Cancer Biol Ther)
This paper reviews evidence for several genomic tests, including Oncotype DX, MammaPrint, Breast Cancer Index, RucurIndex, and EndoPredict, which assist in tailoring adjuvant therapy. Additionally, we explore the role of liquid biopsies in personalizing treatment, emphasizing the importance of considering late relapse risks and potential benefits of extended systemic therapy for HR+/HER2- breast cancer patients.
Journal • Review • Next-generation sequencing
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
4ms
Closing the gap: prognostic and predictive biomarker validation for personalized care in a Latin American hormone-dependent breast cancer cohort. (PubMed, Oncologist)
In summary, we could prove the clinical validity of most transcriptomic-based risk classifiers and their superiority over clinical and immunohistochemical-based methods in the heterogenous, real-world node-negative HR+HER2- MPBCS cohort.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • EndoPredict®
4ms
Eurobio Scientific completes acquisition of Endopredict genomic test from Myriad Genetics (GlobeNewswire)
"Eurobio Scientific...announces the finalisation of its agreement with Myriad Genetics to acquire the EndoPredict genomic test. As part of the agreement announced on 7 May 2024...on 1 August 2024 the Group has completed the acquisition of the second-generation genomic test EndoPredict for breast cancer and the license agreement to distribute the second-generation genomic test Prolaris for prostate cancer from Myriad Genetics. Revenues from these two activities are around €8m on an annual basis, with EBITDA levels in the short and medium term diluting the Group's performance."
M&A • Licensing / partnership • Commercial
|
EndoPredict® • Prolaris®
5ms
Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center. (PubMed)
Chemotherapy was indicated for those who would not receive it before. It was contraindicated in patients who would previously undergo chemotherapy.
Real-world evidence • Journal • Retrospective data • Real-world
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
5ms
Clinical • Case study
|
EndoPredict®
5ms
Real-world evidence • Clinical • Real-world
|
EndoPredict®
5ms
Study of combination of multi-gene assay for luminal type breast cancer (JBCS 2024)
When 0-1 MGA was defined as low-risk and 2-4 MGA as high-risk, the 5-year DRFS was 97.4% for low-risk and 75.5% for high-risk (n=248, n=182, respectively; p=5.5e-11), which was a better prognostic prediction performance than any MGA alone. Discussion By performing Curebest and obtaining microarray data, it was possible to obtain the results of multiple MGAs, and it was suggested that combining each of them may enable more accurate prediction of recurrence
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Curebest™ 95GC Breast • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
5ms
Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays. (PubMed, J Surg Oncol)
This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.
Journal • Review • Clinical
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
6ms
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy. (PubMed, Int J Mol Sci)
Among these tests, Prosigna and EndoPredict® have at present been validated only on a prognostic level, while Oncotype Dx, MammaPrint, and BCI hold both a prognostic and predictive role. Oncologists and pathologists engaged in the management of EBC will find in this review a thorough comparison of available genomic assays, as well as strategies to optimize the utilization of the information derived from them.
Journal • Review
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
6ms
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. (PubMed, Clin Transl Oncol)
In second-line advanced breast cancer, in addition, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and estrogen receptor 1 (ESR1) should be tested in hormone-sensitive cases, BRCA gene mutations in HER2-negative cancers, and in triple-negative breast cancer (TNBC), programmed cell death-1 ligand (PD-L1). Newer biomarkers and technologies, including tumor-infiltrating lymphocytes (TILs), homologous recombination deficiency (HRD) testing, serine/threonine kinase (AKT) pathway activation, and next-generation sequencing (NGS), are at this point investigational.
Journal • Review • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • HRD (Homologous Recombination Deficiency) • PD-1 (Programmed cell death 1) • BRCA (Breast cancer early onset)
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
7ms
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer (clinicaltrials.gov)
P2; Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • PGR negative
|
MammaPrint • EndoPredict®
|
azacitidine
7ms
UK's NICE expands tumor profiling recommendations for guiding adjuvant chemo in early breast cancer (Genomeweb)
"The UK National Institute for Health and Care Excellence (NICE)...recommended three prognostic gene expression tests as tools for guiding adjuvant chemotherapy treatment decisions in an expanded population of early breast cancer patients...In a final guidance, NICE said Myriad Genetics' EndoPredict (which is being sold to Eurobio), Veracyte's Prosigna, and Exact Sciences' Oncotype DX can be used within the National Health Service (NHS) to guide adjuvant treatment for postmenopausal women or men with estrogen receptor-positive, HER2-negative early breast cancer and one to three positive lymph nodes."
NICE
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
7ms
Myriad Genetics announces reorganization of European operations and Sale of EndoPredict business (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States."
Licensing / partnership
|
EndoPredict® • Prolaris®
7ms
Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer. (PubMed)
EndoPredict can guide decisions on adjuvant chemotherapy in early luminal breast cancer. EndoPredict risk stratification is also applicable in premenopausal women.
Journal
|
EndoPredict®
7ms
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial. (PubMed, ESMO Open)
The results confirm the value of EPclin score as an independent prognostic parameter in node-positive, hormone receptor-positive, HER2-negative early breast cancer patients receiving standard adjuvant treatment. EPclin score can be used to identify patients at higher risk of recurrence who may warrant additional systemic treatments.
Journal • P3 data • Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative • PTEN mutation + HR positive
|
EndoPredict®
|
everolimus
7ms
Multi-layered knowledge graph neural network reveals pathway-level agreement of three breast cancer multi-gene assays. (PubMed, Comput Struct Biotechnol J)
Furthermore, through attention analysis, we demonstrated the biological significance and clinical relevance of these subpathways in predicting patient outcomes. The source code is available at http://biohealth.snu.ac.kr/software/ExplainableMLKGNN.
Journal
|
HR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
7ms
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer. (PubMed)
Moreover, preliminary evidence regarding the use of genomic assays to inform de-escalation of endocrine treatment, such as shorter durations or omission, for low risk patients are reviewed. Overall, gene expression assays are emerging as potential tools to further personalize adjuvant treatment for patients with HR+/HER2- breast cancers.
Journal
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
8ms
Effects of Sentinel Lymph Node Biopsy on Decision for Adjuvant Chemotherapy in the Modern Era of Gene Expression Profiling (ASBrS 2024)
Our preliminary results suggest that gene expression profiling holds more weight than nodal status in determining adjuvant therapy. Our study is limited by sample size, and data collection is still ongoing. Premenopausal patients were included for the purpose of this report, but ultimately will be evaluated separately from postmenopausal patients, as in other similar studies.
Clinical • Gene expression profiling • Biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HR positive • HER-2 negative
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
8ms
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
EndoPredict®
9ms
Plasticity marker FOXC1 expression is a superior predictor of Adjuvant Tamoxifen + Chemotherapy efficacy in reducing disease recurrence and all-cause mortality in ER+LN- Breast Cancer: Validation in the SCAN-B Prospective Study (NCT02306096) (ESMO-BC 2024)
Pre-treatment tumor FOXC1 mRNA (on qRTPCR) or protein expression (on IHC) + TS + TG presents a uniquely economical alternative solution to multimarker tests like OncotypeDx, Mammaprint or Endopredict, for guiding therapy of patients diagnosed with ER+LN- breast cancer.
Clinical
|
FOXC1 (Forkhead Box C1)
|
FOXC1 expression
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
tamoxifen
9ms
BIOMARKERS FOR NEOADJUVANT ENDOCRINE THERAPY (GBCC 2024)
Validation of these biomarkers as reliable surrogate endpoints can also lead to a revolution in the clinical trial designs, and potentially avoid the need for repeated tissue biopsies in the surveillance of disease response. Further validation and guidelines for biomarker use will be instrumental in helping standardize the use of NET.
Clinical
|
ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HR positive
|
EndoPredict® • Oncotype DX Breast Recurrence Score®Test
11ms
Circulating tumor DNA (ctDNA) monitoring of estrogen receptor- positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy (YIR 2024)
ctDNA+ patients underwent systemic staging with imaging and randomized to continuation of adjuvant therapy versus switching to fulvestrant plus palbociclib if there was no evidence of distant metastatic disease. ctDNA surveillance of ER+/HER2- breast cancers during adjuvant endocrine therapy indicate 8.3% detection rate at patient level and 3.4% at assay level. Serial screening increases detection rates as 23% of positive ctDNA tests occurred after an initial negative result. 83% of ctDNA+ patients had true molecular relapse without imaging detectable metastatic disease.
Clinical • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative • EGFR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Signatera™ • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
Ibrance (palbociclib) • fulvestrant
11ms
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) (clinicaltrials.gov)
P2; Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide
11ms
RETROSPECTIVE STUDY OF THE IMPACT OF ENDOPREDICT: EXPERIENCE FROM AN HOSPITAL CENTER (ACMG 2024)
ENDOPREDICT PROVED TO BE AN EFFECTIVE THERAPEUTIC DECISION TOOL, WITH FAVORABLE PROGNOSTIC POWER IN WOMEN WITH BREAST CANCER TREATED WITH HORMONOTHERAPY ALONE.
Retrospective data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
|
EndoPredict®
1year
Trial completion • Gold standard • Discordant
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
EndoPredict®
|
tamoxifen
1year
Plasticity marker FOXC1 expression accurately predicts efficacy of Adjuvant Tamoxifen + Chemotherapy in reducing all-cause mortality in ER+LN- Breast Cancer: Validation in the SCAN-B Prospective Study (NCT02306096) (SABCS 2023)
Pre-treatment tumor FOXC1 mRNA or protein expression (assessed using qRT-PCR or routine immunohistochemistry (IHC), respectively, when combined with TS and TG presents a unique and economical alternative solution to multimarker gene panel tests like OncotypeDx®, Mammaprint® or Endopredict®, for guiding therapy of patients diagnosed with ER+LN- breast cancer in resource challenged settings. Such an approach to identify elevated risk of recurrence in patients diagnosed with ER+LN- breast cancer and prevent the same by guiding adjuvant endocrine + chemotherapy decisions, could help to extend recurrence-free and overall survival. Such an approach merits testing in real world ER+LN- patient cohorts in resource-challenged settings to help support implementation of this FOXC1-driven predictive biomarker strategy in the clinic.
Clinical
|
FOXC1 (Forkhead Box C1)
|
FOXC1 expression
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
tamoxifen
1year
Prognostic value of multigene test to the patients with Hormone receptor-positive, HER2-negative breast cancer based on special histologic subtypes (SABCS 2023)
Unfavorable subtypes have shown a significantly higher-risk result of MGT, and patients with unfavorable types of breast cancer and high-risk MGT results have exhibited the worst prognosis. Consequently, we can suggest that MGT can be used as a prognosis evaluation tool for certain special subtypes of breast cancer and further utilized to aid in treatment decisions.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
1year
Association between Histologic Variants and the Results of Multigene Testing in Patients with Hormone Receptor-positive, HER2-negative Invasive Lobular Cancer (SABCS 2023)
In comparison to IDC, the variants of ILC with favorable prognosis show lower rates of high-risk results in MGT, while the variants of ILC with poor prognosis do not differ significantly from IDC. For patients who diagnosed the variants of ILC with poor prognosis, MGT could be useful for prognosis prediction or treatment decision-making.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
1year
Spatially resolved analysis of tumor microenvironment in invasive lobular carcinoma (SABCS 2023)
We identified 4 biologically driven HR+, HER2- ILC groups describing tumor microenvironment heterogeneity. Of note, two of the three groups associated to worse disease outcome were related to metabolism, highlighting the importance of such process in ILC biology and in the future development of new treatment strategies. Moreover, the prognostic power of our index has the potential to refine the assessment of the risk of relapse in ILC.
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
1year
Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy (SABCS 2023)
ctDNA+ patients underwent systemic staging with imaging and randomized to continuation of adjuvant therapy versus switching to fulvestrant plus palbociclib if there was no evidence of distant metastatic disease. ctDNA surveillance of ER+/HER2- breast cancers during adjuvant endocrine therapy indicate 8.3% detection rate at patient level and 3.4% at assay level. Serial screening increases detection rates as 23% of positive ctDNA tests occurred after an initial negative result. 83% of ctDNA+ patients had true molecular relapse without imaging detectable metastatic disease.
Clinical • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Signatera™ • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
Ibrance (palbociclib) • fulvestrant
1year
Comparison of the cost-effectiveness of multigene assays for HR+/HER2- node-negative early-stage breast cancer in the US (SABCS 2023)
Conclusion These results support the use of multigene assays to guide treatment decisions in node-negative HR+/HER2- early-stage breast cancer to improve treatment outcomes, and also result in substantial net cost savings from a societal perspective. The prediction of chemotherapy benefit using the Oncotype DX test resulted in substantially higher cost savings and improved breast cancer outcomes.
HEOR • Cost-effectiveness • Cost effectiveness
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
1year
Chinese expert consensus on multigene testing for adjuvant treatment of HR-positive, HER-2 negative early breast cancer(2023 edition) (PubMed, Zhonghua Zhong Liu Za Zhi)
The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help guide and standardize the clinical use of multigene testing tools and further improve the level of precise treatment for EBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test • RecurIndex®
1year
Trial primary completion date • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
docetaxel • doxorubicin hydrochloride • cyclophosphamide • Kisqali (ribociclib)
1year
Risk score assessment in clinical routine including gene expression testing - Interim Results of the non-interventional study PERFORM evaluating Palbociclib in Combination with Endocrine Therapy for HR+/HER2- Advanced Breast Cancer (DGHO 2023)
704 of 938 pts enrolled between 10/2020 and 09/2022 had ≥6 months follow-up, and 624 pts were evaluable for analysis. Median age was 68 years, 92% were postmenopausal, and 39% presented with de novo ABC whereas 61% had relapse from EBC. Gene expression tests at ID, to predict benefit of adjuvant chemotherapy have been performed in just 3% (Oncotype DX in 50%, Endopredict in 44% and Mammaprint in 6%, respectively).
Combination therapy • Observational data • Clinical • BRCA Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • HRD • BRCA mutation
|
MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
Ibrance (palbociclib)
over1year
Precision medicine in extended adjuvant endocrine therapy for breast cancer. (PubMed, Curr Opin Oncol)
Even after 5 years of adjuvant endocrine therapy, patients with hormone receptor-positive breast cancer have a significant risk for late recurrence, including distant metastases, that might be prevented with longer durations of endocrine therapy. However, the added toxicity and variable benefit derived from extended endocrine therapy make optimal patient selection crucial. Genomic assays are in development to risk-stratify patients for late recurrence and determine efficacy of extended endocrine therapy, with the aim to help guide extended endocrine therapy decisions for clinicians and individualize treatment strategies for patients.
Journal
|
HR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
over1year
Indications for chemotherapy as determined by clinicopathological characteristics vs EndoPredict® and identification of clinicopathological predictors of the gene molecular score (ESSO 2023)
Ki67 and tumor size seem to be the only significant predictors of high-risk EndoPredict®. The nomogram based on our data provided a graphical representation of the predicted probability of the need for chemotherapy and could be used as an additional tool to aid in clinical decision-making.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
EndoPredict®